Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and...
-
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Collaboration combines Intellia’s proprietary genome editing...
-
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis...
-
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis...
-
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
-
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
-
SparingVision Conference Participation in H1 2021 Paris, February 16, 2021 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases,...
-
SparingVision Conference Participation in H1 2021 Paris, February 16, 2021 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases,...
-
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of...
-
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of...